AstraZeneca’s (AZN) Overweight Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their overweight rating on shares of AstraZeneca (LON:AZN) in a report released on Thursday, MarketBeat reports.

A number of other analysts have also issued reports on the stock. Shore Capital restated a “buy” rating and set a £145 target price on shares of AstraZeneca in a research report on Thursday, November 6th. Berenberg Bank lifted their price objective on AstraZeneca from £142 to £145 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research note on Monday, November 10th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of £138.

AstraZeneca Stock Up 0.2%

AZN opened at £140.52 on Thursday. The business has a 50 day moving average price of £137.44 and a 200 day moving average price of £123.76. The firm has a market cap of £217.85 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. AstraZeneca has a twelve month low of GBX 9,573.51 and a twelve month high of £144.10. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

Insiders Place Their Bets

In other AstraZeneca news, insider Nazneen Rahman sold 297 shares of the stock in a transaction on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. Insiders own 0.14% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.